First Manhattan’s Achillion Pharmaceuticals ACHN Stock Holding History

First Manhattan’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-199,731	Closed	-$1.97M	–	1519
2015 Q1	$1.97M	Hold	199,731	–	–	0.01%	347
2014 Q4	$2.45M	Hold	199,731	–	–	0.01%	327
2014 Q3	$1.99M	Hold	199,731	–	–	0.01%	345
2014 Q2	$1.51M	Buy	+199,731	New	+$797K	0.01%	365

Other funds holding ACHN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

First Manhattan's ACHN Position: Q2 2015 in Review

First Manhattan sold out of Achillion Pharmaceuticals (ACHN) in Q2 2015, closing a stake of 199,731 shares — an estimated $1.97M sold.

First Manhattan first reported a position in ACHN in Q2 2014 and held it in 4 quarters. The position peaked at $2.45M in Q4 2014. 158 funds tracked by Wall St. Rank hold ACHN as of Q2 2015.

First Manhattan reported no remaining Achillion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
First Manhattan sold 199,731 Achillion Pharmaceuticals shares in Q2 2015, an estimated $1.97M.
First Manhattan first reported a position in Achillion Pharmaceuticals in Q2 2014 and held it in 4 quarters.
First Manhattan's Achillion Pharmaceuticals position peaked at $2.45M in Q4 2014.
158 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2015.

Based on First Manhattan's 13F filing for Q2 2015, filed 17 Jul 2015.